0001213900-22-054066.txt : 20220906 0001213900-22-054066.hdr.sgml : 20220906 20220906083451 ACCESSION NUMBER: 0001213900-22-054066 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20220906 FILED AS OF DATE: 20220906 DATE AS OF CHANGE: 20220906 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medigus Ltd. CENTRAL INDEX KEY: 0001618500 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37381 FILM NUMBER: 221226971 BUSINESS ADDRESS: STREET 1: 3 HANECHOSHET STREET, BUILDING B CITY: TEL AVIV STATE: L3 ZIP: 6971068 BUSINESS PHONE: 972722602211 MAIL ADDRESS: STREET 1: 3 HANECHOSHET STREET, BUILDING B CITY: TEL AVIV STATE: L3 ZIP: 6971068 6-K 1 ea165381-6k_medigusltd.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2022

 

Commission File Number 001-37381

 

MEDIGUS LTD.
(Translation of registrant’s name into English)

 

3 HaNechoshet Street, building B, 6971068, Tel Aviv, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒  Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   __

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   __

 

 

 

 

 

 

EXPLANATORY NOTE

 

On September 6, 2022, Medigus Ltd. issued a press release titled: “Medigus: Eventer Achieved Record Revenues increase of 211% Year-Over-Year to Approximately $1.4 Million in The First Half of 2022.” A copy of this press release is furnished herewith as Exhibit 99.1.

 

1

 

 

EXHIBIT INDEX

 

Exhibit   Description
     
99.1   Press release dated September 6, 2022

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MEDIGUS LTD.
     
Date: September 6, 2022  By: /s/ Tali Dinar
    Tali Dinar
    Chief Financial Officer

 

 

 

3

 

 

 EX-99.1 2 ea165381ex99-1_medigusltd.htm PRESS RELEASE DATED SEPTEMBER 6, 2022

Exhibit 99.1 

 

 

 

Medigus: Eventer Achieved Record Revenues increase of 211% Year-Over-Year to Approximately $1.4 Million in The First Half of 2022

 

Eventer’s turnover from tickets sales for the first half of 2022 amounted to approx. $35 million an increase of approx. 307% compared to the first half of 2021

 

Tel Aviv, Israel – September 6, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that its 46.21% owned subsidiary, Eventer Technologies Ltd. (“Eventer”), a developer of technology platform enabling producers and venues to create virtual conferences and events including a smart ticketing solution, achieved record high financial results for the first six months of 2022.

 

Eventer’s first half of 2022 highlights:

 

●Eventer’s overall turnover from ticket sales for the first half of 2022 amounted to approx. $35 million, compared to approx. $8.6 million in the first half of 2021, an increase of approx. 307% and an increase of approx. 35% compared to the entire year of 2021

 

●Over 1 million tickets were sold using Eventer’s online platform during the first half of 2022

 

●Eventer retained its commission rate through the first six months of 2022 at approx. 5%, equal to the first six months of 2021

 

●Eventer’s revenues for the first half of 2022 totaled at approx. $1.4 million, an increase of approx. 211% compared to approx. $0.45 million in the first half of 2021

 

●Eventer’s gross profit for the first half of 2022 amounted to approx. $1.17 million, an increase of approx. 350% compared to approx. $0.26 million in the first half of 2021 and an increase of approx. 45% compared to the entire year of 2021

 

Liron Carmel, Chief Executive Officer of Medigus, commented, “We are excited about the great results presented by Eventer for the first half of 2022. The recovery of the entertainment industry from Covid-19 has positive effects on Eventer, which surpasses its pre-pandemic performance. During the first half of 2022, Eventer expanded its outreach to address new market verticals, including the field of sports events, which is a sector with great potential for Eventer and virtual events.”

 

Eventer has developed a unique event management system that allows its customers to increase sales volume and reduce the resources invested in marketing tools solely intended to increase exposure and sales. Eventer has an exclusive license to use the Screenz.live platform that offers high-quality video conferencing for thousands of participants.

 

 

 

 

About Medigus

 

Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technology company focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce and electric vehicle markets. Medigus’ affiliations in the medical solutions arena include ownership in Polyzion Ltd. and ownership in industry 4.0 company, ScoutCam Inc. The Company’s affiliates in digital commerce include Gix Internet Ltd., Jeffs’ Brands Ltd. and Eventer Technologies Ltd. In the electric vehicle market, Charging Robotics Ltd. and Revoltz Ltd. are also part of the Company’s portfolio of technology solution providers. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Medigus’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Eventer could differ materially from those described in or implied by the statements in this press release.

 

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise required by law, Medigus undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Medigus is not responsible for the contents of third-party website

 

Company Contact:

 

Tali Dinar

Chief Financial Officer

+972-8-6466-880

ir@medigus.com

 

Investor Relations Contact:

Miri Segal

CEO

MS-IR LLC

+1-917-607-8654

msegal@ms-ir.com

 

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end